Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRACIE phase II study of ivonescimab plus chemotherapy in advanced gastric and gastroesophageal adenocarcinoma
2025-520694-39-00Phase 2Authorised
- Sponsor
- Unicancer
- Start
- Sep 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ivonescimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Unicancer. Primary endpoint: Objective response rate by central review. Planned start Sep 2025; status: authorised.
02
Drugs
ivonescimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2025-520694-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520694-39-00.